| 范丽莉,许文林,彭金娟,李 丽,陶 凯.他莫昔芬辅助治疗的ER阳性乳腺癌患者miR-122、miR-449a检测的
临床价值研究[J].,2024,(23):4592-4594 |
| 他莫昔芬辅助治疗的ER阳性乳腺癌患者miR-122、miR-449a检测的
临床价值研究 |
| Study on the Clinical Value of miR-122 and miR-449a Detectionin ER-Positive Breast Cancer Patients Treated with Tamoxifen |
| 投稿时间：2024-07-24 修订日期：2024-08-29 |
| DOI：10.13241/j.cnki.pmb.2024.23.054 |
| 中文关键词: ER阳性乳腺癌 他莫昔芬 miR-122 miR-449a 预后 |
| 英文关键词: ER- positive breast cancer Tamoxifen miR-122 miR-449a Prognosis |
| 基金项目:镇江市妇产疾病临床医学研究中心开放课题项目（SS2022003-KFD01）；江苏省自然科学基金资助项目（BK20141288） |
|
| 摘要点击次数: 17 |
| 全文下载次数: 10 |
| 中文摘要: |
| 摘要 目的：分析他莫昔芬辅助治疗的雌激素受体（ER）阳性乳腺癌患者微小RNA（miR）-122、miR-449a检测的临床价值。方法：选择258例ER阳性乳腺癌患者，均接受他莫昔芬辅助治疗。分析血清外泌体miR-122、miR-449a表达与患者临床病理特征的关系。随访5年，绘制Kaplan-Meier曲线分析生存率，采用多因素Cox回归分析影响因素。结果：组织学分级3级、TNM分期Ⅲ期、腋窝淋巴结转移、Ki-67高表达的ER阳性乳腺癌患者治疗前血清外泌体miR-122高于组织学分级1-2级、TNM分期Ⅰ/Ⅱ期、无腋窝淋巴结转移、Ki-67低表达，miR-449a则更低（P<0.05）。miR-122高表达组中位总生存期（OS）低于miR-122低表达组（P＜0.05）；miR-449a低表达组中位OS低于miR-449a高表达组（P＜0.05）；Cox回归分析显示TNM分期为Ⅲ期、Ki-67 高表达（≥14%）、miR-122高表达、miR-449a低表达是ER阳性乳腺癌患者他莫昔芬辅助治疗预后不良的独立危险因素（P＜0.05）。结论：ER阳性乳腺癌患者血清外泌体miR-122、miR-449a表达水平与患者组织学分级、TNM分期、腋窝淋巴结转移情况、Ki-67表达等临床病理特征相关，miR-122高表达、miR-449a低表达是影响患者5年生存期的独立危险因素，有望成为预测他莫昔芬辅助治疗预后的重要标志物。 |
| 英文摘要: |
| ABSTRACT Objective: To analyze the clinical value of minimal RNA (miR) -122 and miR-449a detection in estrogen receptor (ER) -positive breast cancer patients treated with adjuvant tamoxifen. Methods: 258 ER-positive breast cancer patients were selected, and all patients treated with tamoxifen. The relationship between the expression of serum exosomal miR-122 and miR-449a and the clinicopathological characteristics of patients were analyzed. 5 years after follow-up, the survival rate was analyzed by Kaplan-Meier curve, and the influencing factors was analyzed by multivariate Cox regression. Results: The serum exosomal miR-122 of ER positive breast cancer patients with histological grade 3, TNM stage III, axillary lymph node metastasis and high expression of Ki-67 before treatment was higher than that of histological grade 1-2, TNM stage I/II, no axillary lymph node metastasis and low expression of Ki-67, and miR-449a was lower (P<0.05). The median overall survival (OS) of miR-122 high expression group was lower than that of miR-122 low expression group (P<0.05). The median OS of miR-449a low expression group was lower than that of miR-449a high expression group (P<0.05). Cox regression analysis showed that TNM stage III, high expression of Ki-67 (≥14 %), high expression of miR-122 and low expression of miR-449a were independent risk factors for poor prognosis of tamoxifen adjuvant therapy in ER-positive breast cancer patients (P<0.05). Conclusion: The expression levels of serum exosomal miR-122 and miR-449a in ER-positive breast cancer patients are correlated with TNM stage III and high expression of Ki-67, the high expression of miR-122 and the low expression of miR-449a are independent risk factors affecting the 5-year survival of patients, It is expected to be an important marker for predicting the prognosis of tamoxifen adjuvant therapy. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
